ClinicalTrials.gg
Not yet recruitingNCT06348654InPERSONUpdated Apr 5, 2024

New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast Cancer

An observational study in Breast Cancer, Narrative Medicine and HER2-negative Breast Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 19 open to participants now, 23 under way, none of them phase 3. Breast Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Planned enrollment
21st of 24
50 · median 288
Started
2024
with 3 others
Observational
24 of 32
16 open now
Primary completion
2024-12
later than 5 of 22 live
Registered
18th of 32
by date

Among the 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 21st largest by planned enrollment of the 24 observational ones that give a count, is one of 4 that started in 2024, is one of 24 observational ones, reaches primary completion later than 5 of the 22 other live ones, and was the 18th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, or all of them as a file.
02

Study summary

The goal of the InPerson study is to employ all resources in a digital listening platform to benefit the quality of life of patients (QoL) with advanced HER2-negative breast cancer.

The care pathway of patients with this type of disease represents an optimal setting for the implementation of an innovative narrative medicine pathway that, aided by integrative therapies, aims to support and accompain them in their treatment journey with a continuum of care. Moreover, the narrative medicine platform will implement the actual "static" way to define QoL with the classic Patient-Reported Outcomes (PROs) questionnaires, that reflect the patient status at a certain time point and not as a dinamic entity. It is on the basis of these assumptions that the present application project on the use of the DNMLAB digital narrative diary in the oncology department of the Fondazione Policlinico Gemelli was born.

Read the detailed description

In recent years, the health care system has undergone significant changes that have led to the emergence of a person-centered medicine paradigm. In this new scenario, outcomes of care pathways are evaluated not only on the basis of clinical outcomes but also in terms of the impact on patients' quality of life. Due to therapeutic advances, it therefore becomes increasingly necessary to adopt integrated, empathic and person-centered clinical approaches that also take into account patients' needs and expectations for care.

New measurement tools that assess also the patient's perspective have been introduced into clinical practice.

Among these new tools are Patient-Reported Outcome Measures (PROMs), aimed at determining patients' perceived quality of life during treatment and follow-up. Systematic collection of patient-reported outcomes has indeed been proven to be a valid, reliable, and accurate methodology in oncology, both for assessing treatment outcomes and monitoring drug toxicity, and for avoiding all those cases where impacts and symptoms are overlooked or underestimated by clinicians.

However, currently approved and standardized questionnaires do not comprehensively inform clinicians about how the disease and treatments affect the patient's care pathway.

In this context, narrative medicine, on the other hand, has proven to be a valid and reliable methodology capable of integrating the patient's perspective into standard clinical assessment.

Qualitative narrative medicine methodologies have been recognized as useful and effective to the extent that they allow clinicians to access the existential and emotional components of patients' experience of care, and for their ability to enrich the information expressed in standardized questionnaires. Narrative methodologies thus make it possible to capture perceptions of quality of life, and thus to capture a highly subjective dimension influenced by each individual's needs and expectations (e.g., relative deprivation).

Narrative medicine has also been shown to be feasible and reliable in improving doctor-patient communication and promoting bio-psycho-social personalization of the care pathway, particularly when used in combination with digital listening tools, such as the digital narrative diary. Studies on digital narrative medicine in oncology have shown the potential of digital platforms in promoting listening to patient needs, especially when listening is done by a multidisciplinary care team throughout the care pathway. It has also been seen how digital has a positive impact not only on the patient but also, more broadly, on the entire care team.

The transition from a traditional, disease-centered model of care to a new, more person-centered model of care has since led to the introduction of integrative medicine in cancer treatment centers. Through the rational and evidence-based use of lifestyle, psychological support, and complementary therapies, integrative medicine promotes better control of side effects, greater adherence to treatment protocols, and optimization of patients' quality of life throughout the care pathway. In the case of breast cancer, integrative oncology combines conventional cancer treatments with integrative therapies in order to support women in their bio-psycho-social dimensions, thus providing effective and minimally invasive responses to complex and sometimes unmet health needs.

03

Conditions studied

  • Breast Cancer
  • Narrative Medicine
  • HER2-negative Breast Cancer
  • Patient Satisfaction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population refers to women with HER2-negative advanced breast cancer (IHC score 0, 1+ or 2+ with unamplified FISH/SISH) in first- or second-line treatment, with advanced disease, undergoing cancer treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -negative advanced disease undergoing first- or oncological treatment combined with integrative therapies;
  • Age ≥18 years;
  • Knowledge of Italian language;
  • ≥24 weeks.

In case the patient is unable to actively participate, the caregiver can act as a vicarious narrator and contribute to the study by supplementing the patient's contribution.

Exclusion criteria

Exclusion Criteria:

  • Performance Status >2;
  • Inability to participate in the study due to psychiatric disorders;
  • Unavailability of an e-mail account or unwillingness to use web-based tools.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • Behavioralintroduction of digital listening may improve the quality of life of patients withe breast cancer

    Introduction of a digital listening and communication pathway aimed at improving the quality of life of patients with advanced HER2-negative breast cancer

06

What researchers measure

Primary outcomes

  1. Standardized quality-of-life measurement

    The integration of standardized quality-of-life measurement with the patient's subjective narrative through the application of validated narrative medicine methodologies. Primarily QoL questionnaires from EORTC QLQC-30 and QLQ-BR23, implemented with digital narrative tehniques.

    Time frame: 12 months

  2. Perceived quality of life

    The improvement of the perceived quality of life of patients with advanced breast cancer,Primarily QoL questionnaires from EORTC QLQC-30 and QLQ-BR23, implemented with digital narrative tehniques.

    Time frame: 12 months

  3. Personalization of the care pathway

    Personalization of the care pathway through integrative therapies, based on patients' needs, attitudes and lifestyles. This does not necessarily need standardized questionnaires, because if the patient raise concern about a sign or symptom, this will be properly evaluated with the last CTCAE available version.

    Time frame: 12 months

  4. Quality of the patient-physician relationship.

    The improvement of the quality of the patient-physician relationship. This is not necessary linked to a standardized evaluation method or solely to an improvement in QoL measured with the already cited questionnaires. Dedicated perception scales will be created by the digital narrative team to explore if the proposed methods are feasible.

    Time frame: 12 Months

Secondary outcomes

  1. Interaction between multidisciplinary teams

    The strengthening of interaction between multidisciplinary teams. Personalization of the care pathway implicitly needs the involvement of other professional figures: psychologist, antropologist, radiotherapist, dietician, integrative care specialist. Based on this, the team will try to develop a "holistic" care pathway, tailored on the single patient.

    Time frame: 12 months

  2. Patient involvement and compliance in the care pathway

    The validation of digital tools to introduce innovative models of patient involvement and compliance in the care pathway. The continuos feedback from the oncologist based on the narrative diary will help the clinician to estimate the treatment compliance and the possible side effects.

    Time frame: 12 Months

  3. lifestyles best suited to positively affect quality of life

    The enhancement of communication processes aimed at informing metastatic patients about lifestyles best suited to positively affect quality of life. Through the collaboration with the integrative care team, if needed, a change in lifestyle with a structured schedule will be proposed to each single patient.

    Time frame: 12 Months

  4. Awareness of disease condition

    Increasing patients' awareness of their disease condition, the effects of treatment, and the care needs that may arise during treatment. The diary gives to the patient the opportunity to develop an introspective dimension of the disease, and stimulates her to properly elaborate the steps of the care pathway.

    Time frame: 12 Months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Dec 2024, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 5, 2024
StartEst.
Mar 30, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Jan 1, 2025
Last update
Apr 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06348654
Responsible party
FABI ALESSANDRA (Principal Investigator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Apr 5, 2024
Start date
Mar 30, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Apr 5, 2024

Study contacts

Fabi Alessandra
Contact
alessandra.fabi@policlinicogemelli.it
+39.0630157337
Fabi Alessandra
principal investigator · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion